<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <title>#023: March 15, 2021 - Longevity Marketcap Telemetry - Hex Index</title>
  <link rel="stylesheet" href="../../styles.css">
</head>
<body class="reading-mode">
  <header class="reading-header">
    <a href="../../index.html" class="back-link">&larr; Back to Library</a>
  </header>
  <main class="reading-content">
    
    <article class="article-page">
      <header class="article-header">
        <h1>#023: March 15, 2021 - Longevity Marketcap Telemetry</h1>
        <div class="article-meta">
          <span class="author">By Nathan Cheng</span>
          <span class="separator">&middot;</span>
          <a href="../../publication/longevitymarketcap/index.html" class="publication">
            Longevity Marketcap
          </a>
          <span class="separator">&middot;</span><time>Mar 15, 2021</time>
          <span class="separator">&middot;</span>
          <span class="read-time">9 min read</span>
        </div>
      </header>

      

      <div class="article-excerpt">
        <h1><strong>üì° </strong>Longevity Marketcap Telemetry (March 15th, 2021)</h1><div class="captioned-image-container"><figure><a class="image-link image2 is-viewable-img" target="_blank" href="https://substackcdn.com/image/fetch/$s_!w-0b!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fbucketeer-e05bbc84-baa3-437e-9518-adb32be77984.s3.amazonaws.com%2Fpublic%2Fimages%2Ff4c9829e-e35b-47f2-a5d4-1e7acbd2e753_1200x500.png" data-component-name="Image2ToDOM"><div class="image2-inset"><picture><source type="image/webp" srcset="https://substackcdn.com/image/fetch/$s_!w-0b!,w_424,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fbucketeer-e05bbc84-baa3-437e-9518-adb32be77984.s3.amazonaws.com%2Fpublic%2Fimages%2Ff4c9829e-e35b-47f2-a5d4-1e7acbd2e753_1200x500.png 424w, https://substackcdn.com/image/fetch/$s_!w-0b!,w_848,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fbucketeer-e05bbc84-baa3-437e-9518-adb32be77984.s3.amazonaws.com%2Fpublic%2Fimages%2Ff4c9829e-e35b-47f2-a5d4-1e7acbd2e753_1200x500.png 848w, https://substackcdn.com/image/fetch/$s_!w-0b!,w_1272,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fbucketeer-e05bbc84-baa3-437e-9518-adb32be77984.s3.amazonaws.com%2Fpublic%2Fimages%2Ff4c9829e-e35b-47f2-a5d4-1e7acbd2e753_1200x500.png 1272w, https://substackcdn.com/image/fetch/$s_!w-0b!,w_1456,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fbucketeer-e05bbc84-baa3-437e-9518-adb32be77984.s3.amazonaws.com%2Fpublic%2Fimages%2Ff4c9829e-e35b-47f2-a5d4-1e7acbd2e753_1200x500.png 1456w" sizes="100vw"><img src="https://substackcdn.com/image/fetch/$s_!w-0b!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fbucketeer-e05bbc84-baa3-437e-9518-adb32be77984.s3.amazonaws.com%2Fpublic%2Fimages%2Ff4c9829e-e35b-47f2-a5d4-1e7acbd2e753_1200x500.png" width="1200" height="500" data-attrs="{&quot;src&quot;:&quot;https://bucketeer-e05bbc84-baa3-437e-9518-adb32be77984.s3.amazonaws.com/public/images/f4c9829e-e35b-47f2-a5d4-1e7acbd2e753_1200x500.png&quot;,&quot;srcNoWatermark&quot;:null,&quot;fullscreen&quot;:null,&quot;imageSize&quot;:null,&quot;height&quot;:500,&quot;width&quot;:1200,&quot;resizeWidth&quot;:null,&quot;bytes&quot;:null,&quot;alt&quot;:null,&quot;title&quot;:null,&quot;type&quot;:null,&quot;href&quot;:null,&quot;belowTheFold&quot;:false,&quot;topImage&quot;:true,&quot;internalRedirect&quot;:null,&quot;isProcessing&quot;:false,&quot;align&quot;:null,&quot;offset&quot;:false}" class="sizing-normal" alt="" srcset="https://substackcdn.com/image/fetch/$s_!w-0b!,w_424,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fbucketeer-e05bbc84-baa3-437e-9518-adb32be77984.s3.amazonaws.com%2Fpublic%2Fimages%2Ff4c9829e-e35b-47f2-a5d4-1e7acbd2e753_1200x500.png 424w, https://substackcdn.com/image/fetch/$s_!w-0b!,w_848,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fbucketeer-e05bbc84-baa3-437e-9518-adb32be77984.s3.amazonaws.com%2Fpublic%2Fimages%2Ff4c9829e-e35b-47f2-a5d4-1e7acbd2e753_1200x500.png 848w, https://substackcdn.com/image/fetch/$s_!w-0b!,w_1272,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fbucketeer-e05bbc84-baa3-437e-9518-adb32be77984.s3.amazonaws.com%2Fpublic%2Fimages%2Ff4c9829e-e35b-47f2-a5d4-1e7acbd2e753_1200x500.png 1272w, https://substackcdn.com/image/fetch/$s_!w-0b!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fbucketeer-e05bbc84-baa3-437e-9518-adb32be77984.s3.amazonaws.com%2Fpublic%2Fimages%2Ff4c9829e-e35b-47f2-a5d4-1e7acbd2e753_1200x500.png 1456w" sizes="100vw" fetchpriority="high"></picture><div class="image-link-expand"><div class="pencraft pc-display-flex pc-gap-8 pc-reset"></div></div></div></a></figure></div><ol><li><p>Announcements</p></li><li><p>Last Week in Longevity</p></li><li><p>Longevity Futures</p></li><li><p>Longevity Jobs</p></li><li><p>Tweet of the Week</p></li></ol><p><em>*<strong>Disclaimer</strong>: None of this should be taken as financial advice. It is for educational purposes only.</em></p><p><em>**<strong>Resources</strong>: <a href="https://longevitymarketcap.com/longevity-trial-tracker/">Longevity Clinical Trial Tracker </a>// <a href="https://longevitylist.com/longevity-industry-database/">Longevity Industry Database</a></em></p><div><hr></div><h2>üì¢ Announcements</h2><ol><li><p>The newsletter will be split into <strong>two separate publications (both free)</strong> going forward:</p><ol><li><p><strong>Longevity Marketcap Telemetry</strong> - A weekly review of major developments in the longevity industry, upcoming events, jobs, investment opportunities (‚ÄúDeal Flow‚Äù), and short observations.&nbsp;</p></li><li><p><strong>Longevity Marketcap Reports </strong>- A more in-depth research report on longevity companies and their underlying science published every 1 - 2 weeks. Easier to use as reference material now that all the extraneous news and events are moved to a separate publication (see above).&nbsp;</p></li></ol></li><li><p><a href="https://patreon.com/nathancheng">I started a Patreon account</a>. This newsletter and the LMC research reports will always be free. <strong>But if you believe in me and my mission to grow a wave of passionate people building, funding, and championing technologies that will </strong><em><strong>accelerate the end of aging</strong></em> then please consider supporting. Your funding will help me pay for web server costs, graphic design and video production tools, and perhaps hire some extra help in the future</p></li></ol><h3>Special note: PEARL Trial by AgelesssRX</h3><div id="youtube2-GU70PAoWdU8" class="youtube-wrap" data-attrs="{&quot;videoId&quot;:&quot;GU70PAoWdU8&quot;,&quot;startTime&quot;:&quot;1s&quot;,&quot;endTime&quot;:null}" data-component-name="Youtube2ToDOM"><div class="youtube-inner"><iframe src="https://www.youtube-nocookie.com/embed/GU70PAoWdU8?start=1s&amp;rel=0&amp;autoplay=0&amp;showinfo=0&amp;enablejsapi=0" frameborder="0" loading="lazy" gesture="media" allow="autoplay; fullscreen" allowautoplay="true" allowfullscreen="true" width="728" height="409"></iframe></div></div><p>AgelessRX, a DTC online pharmacy for anti-aging compounds, is crowdfunding a 200-person Phase 4 clinical trial of rapamycin. Rapamycin is one of the most well-studied anti-aging drugs (for <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4906330/">mice it extends lifespan</a> ~ +15%). But because it is off-patent there is no profit incentive for pharma companies to conduct a clinical trial.&nbsp;</p><p>AgelessRX is looking to raise a total of $800k from two sources:&nbsp;</p><ol><li><p>Trial participants ($1000 / each) who will receive $3000 worth of biomarker testing during the trial (DNA methylation clock, blood tests, glycation age test, DEXA scans, gut microbiome sequencing, etc)&nbsp;</p></li><li><p>Donations from individuals and organizations.&nbsp;</p></li></ol><p>It appears AgelessRX is only $200k away from reaching its goal for donations. If you are interested in either enrolling for the trial or donating please check out the <a href="https://www.agelessrx.com/pearl">PEARL trial webpage</a>.</p><div><hr></div><h2><strong>üìù </strong>Last Week in Longevity</h2><ul><li><p><strong><a href="https://www.longevity.technology/swiss-longevity-company-builder-launches/">Maximon, Swiss-based venture builder, to invest 50M+ in longevity companies over four years</a>. </strong>Founded by notable entrepreneur-investors Marc Bernegger, Tobias Reichmuth, and J√∂rg Rieker, Maximon aims to partner with entrepreneurs to build longevity companies from scratch. Bernegger and Reichmuth are also the organizers of the <a href="https://www.longevityinvestors.ch/">Longevity Investors Conference</a>. <br><br>So </p></li></ul>...</source>
      </div>

      <div class="read-full-article">
        <a href="https://sub.longevitymarketcap.com/p/023-march-15-2021-longevity-marketcap" class="read-button" target="_blank" rel="noopener">
          Read full article on Longevity Marketcap &rarr;
        </a>
        <p class="copyright-note">
          This excerpt is provided for preview purposes.
          Full article content is available on the original publication.
        </p>
      </div>
    </article>
  
  </main>
</body>
</html>